Financials in USD. Standardized financial statements.
A compact view of how Lipella Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue? | $536,357 | $449,617 | $184,156 | $259,347 | $961,683 | $694,748 |
| Revenue Growth? | +19.3% | +144.2% | -29.0% | -73.0% | +38.4% | 0.0% |
| Cost of Revenue? | $3.61M | $3.04M | $2.55M | $1.46M | $975,960 | $682,891 |
| Gross Profit? | -$3.08M | -$2.59M | -$2.36M | -$1.20M | -$14,277 | $11,857 |
| Gross Margin? | -573.7% | -575.9% | -1283.4% | -461.7% | -1.5% | +1.7% |
| Operating Expenses? | $2.00M | $2.16M | $226,192 | $718,384 | $42,585 | $65,648 |
| Operating Income? | -$5.08M | -$4.75M | -$2.59M | -$1.92M | -$56,862 | -$53,791 |
| EBITDA? | -$5.01M | -$4.61M | -$2.59M | -$1.86M | -$53,691 | $0 |
| Income Before Tax | -$5.02M | -$4.62M | -$2.60M | -$1.87M | -$61,656 | -$61,848 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$5.02M | -$4.62M | -$2.60M | -$1.87M | -$61,656 | -$61,848 |
| EPS? | $-4.79 | $-6.16 | $-5.12 | $-4.00 | $-0.23 | $-0.24 |
| Diluted EPS? | $-4.79 | $-6.16 | $-5.12 | $-4.38 | $-0.23 | $-0.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality